Fibrinolytic protease

Fibrinolytic proteases are a specialized class of enzymes, primarily serine proteases, that play a fundamental role in the dissolution of blood clots by degrading fibrin polymers [1, 3]. The most prominent endogenous member is plasmin, which is generated from its inactive precursor, plasminogen, by plasminogen activators such as tissue-type plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA) [1, 11]. Beyond their role in maintaining vascular patency, these enzymes are involved in broader physiological processes, including extracellular matrix remodeling, cell migration, and the modulation of immune responses [6, 10]. Pathologically, an imbalance in the fibrinolytic system is a key driver of thrombotic disorders such as myocardial infarction, ischemic stroke, and pulmonary embolism [3, 5]. In therapeutic contexts, recombinant versions of these proteases or their activators are administered as thrombolytic agents to rapidly dissolve occlusive thrombi and restore blood flow to vital organs [2, 4]. Drugs like alteplase and tenecteplase are engineered to be fibrin-specific, targeting plasminogen activation primarily at the site of the clot to minimize systemic effects [5, 8]. However, the clinical use of these agents is strictly managed due to the high risk of severe bleeding complications, most notably intracranial hemorrhage, which arises from the non-specific degradation of circulating fibrinogen and other clotting factors [11].

Other names

Thrombolytic enzymePlasminogen activatorFibrinolytic enzymeClot-busting enzyme

Fibrinolytic proteases act through two primary mechanisms: indirect activation, where agents like alteplase and streptokinase convert the zymogen plasminogen into active plasmin; and direct fibrinolysis, where enzymes like nattokinase or lumbrokinase directly cleave fibrin polymers. Both pathways result in the degradation of the fibrin matrix, leading to the dissolution of blood clots.